Clinical Trial

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated August 1, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of this study is to assess the safety, efficacy, pharmacokinetics and immunogenicity of HS-20117 combined with Aumolertinib in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \[Exon 19del\] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-12; most recent amendment 2025-07-30.
Status change: Not Yet Recruiting → Recruiting 2025-07-30
Trial Details
NCT Number NCT06417008
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Non-Squamous Non-Small Cell Lung Cancer
Enrollment 1,080 participants
Start Date 2024-05-28
Primary Completion 2026-06-01 (estimated)
Study Completion 2030-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-01